Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Technological advancements in virtual clinical trials
3.2.1.2 Rising penetration of technology in healthcare
3.2.1.3 Development of novel medications for various diseases
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory framework
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.5.1 Supplier power
3.5.2 Buyer power
3.5.3 Threat of new entrants
3.5.4 Threat of substitutes
3.5.5 Industry rivalry
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive positioning matrix
4.4 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Study Design, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Interventional
5.3 Observational
5.4 Expanded access
Chapter 6 Market Estimates and Forecast, By Type, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Fully virtual trials
6.3 Hybrid virtual trials
Chapter 7 Market Estimates and Forecast, By Phases, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Phase I
7.3 Phase II
7.4 Phase III
7.5 Phase IV
Chapter 8 Market Estimates and Forecast, By Indication, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 CNS
8.3 Autoimmune/inflammation
8.4 Cardiovascular disease
8.5 Metabolic/endocrinology
8.6 Infectious disease
8.7 Oncology
8.8 Genitourinary
8.9 Ophthalmology
8.10 Other indications
Chapter 9 Market Estimates and Forecast, By Industry, 2018 – 2032 ($ Mn)
9.1 Key trends
9.2 Pharmaceutical and biotechnology companies
9.3 Contract research organizations (CROs)
9.4 Medical devices companies
9.5 Other industries
Chapter 10 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
10.1 Key trends
10.2 North America
10.2.1 U.S.
10.2.2 Canada
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 France
10.3.4 Spain
10.3.5 Italy
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4 Australia
10.4.5 Rest of Asia Pacific
10.5 Latin America
10.5.1 Brazil
10.5.2 Mexico
10.5.3 Rest of Latin America
10.6 Middle East and Africa
10.6.1 South Africa
10.6.2 Saudi Arabia
10.6.3 Rest of Middle East and Africa
Chapter 11 Company Profiles
11.1 Clinical Ink
11.2 CROPRIME Ltd
11.3 ICON, plc
11.4 IQVIA Inc.
11.5 Medable, Inc.
11.6 Medidata
11.7 Oracle Corporation
11.8 Parexel International (MA) Corporation
11.9 PRA Health Sciences
11.10 Signant Health
